Education

Bone Club Webinar series

Three-Part Webinar Series

Join SIO for an intermediate-level (200) musculoskeletal (MSK) three-part webinar series. Part one will focus on the interventional treatment of malignant and metastatic bone lesions in both the axial and appendicular skeleton, covering fixation techniques like ablation, cementation, and embolization. Part two will focus on the finer details of patient evaluation and procedural techniques for benign bone lesions, demonstrating bone grafting for UBC/ABC. Part three addresses the general guidelines and physiology for the management of oncologic pain using cryoneurolysis, techniques for managing chest wall masses and ablative options for management of aggressive pelvic disease tumors.

To get the most out of the series, we recommend registering for all three sessions.

Part 1: How I Do It—From Imaging Workup to Intervention: Metastatic/Malignant Bone Lesions

Wednesday, 24 September 2025 | 7 – 8:30 p.m. ET

Faculty

Moderator

Gina Landinez, MD

Baptist Health South Florida, Miami Cadiac and Vascular Institute

Faculty Panel

Jason Levy MD, FSIR

Northside Radiology Associates

Marwan Moussa, MD

Beth Israel Deaconess Medical Center

Brandon Key, MD

Froedtert & Medical College of Wisconsin

Watch On-Demand

Part 2: How I Do It—From Imaging Workup to Intervention: Benign MSK Lesions

Wednesday, 8 October 2025 | 7 – 8:30 p.m. ET

Faculty

Moderator

Thedore Vander Velde, MD

Mallinckrodt Institute of Radiology

Faculty Panel

James Murakami, MD, MS

Nationwide Children's Hospital

Shankar Rajeswaran, MD

Northwestern University

Eric Monroe, MD

University of Wisconsin

Watch On-Demand

Part 3: How I Do It—From Imaging Workup to Intervention: Cryoneurolysis for Pain

Tuesday, 11 November 2025 | 7 – 8:30 p.m. ET

Faculty

Moderator

Sirish Kishore, MD

Stanford University

Faculty Panel

Junjian Huang, MD

Emory Healthcare

Shantanu Warhadpande MD

University of Michigan

John David Prologo, MD

Emory Healthcare

The Bone Club webinar series is supported by:

HCC Webinar Series

Join SIO for a three-part webinar series on hepatocellular carcinoma (HCC) this fall. Part one will cover advances in treatment with a shift toward combination therapies and sequencing strategies to optimize patient outcomes. Part two will explore the role of immunotherapy in HCC, including combinations with locoregional therapies, mechanisms of resistance, biomarker predictions and other therapeutic targets. Part three will highlight ongoing critical trials of combination locoregional therapy and immunotherapy in the liver.

To get the most out of the series, we recommend registering for all three sessions.

Part 1: Advancing HCC Treatment: Sequencing Strategies and Managing Combination Therapies

Tuesday, 30 September 2025 | 7:00–8:00 p.m. ET

Faculty

Moderator

Julius Chapiro, MD, PhD

Yale University

Faculty Panel

Richard Finn, MD

University of California Los Angeles

Nicholas Fidelman, MD

University of California San Francisco

Watch On-Demand

Part 2: Integrating Immunotherapy with Locoregional Therapies in HCC: Mechanisms, Biomarkers, and Resistance

Wednesday, 22 October 2025 | 7:00–8:00 p.m. ET

Faculty

Moderator

Julius Chapiro, MD, PhD

Yale University

Faculty Panel

Terence Gade, MD, PhD

University of Pennsylvania

Sarah Manes

Global Liver Institute

Anjana Pillai, MD

University of Chicago

Michael Soulen, MD, FSIR, FCIRSE

University of Pennsylvania

Watch On Demand

Part 3: Ongoing Critical Trials of Combination Locoregional Therapy and Immunotherapy in the Liver

Tuesday, 4 November 2025 | 7:00–8:30 p.m. ET

This webinar is sponsored by:

Faculty

Moderator

Zach Berman, MD

UC San Diego

Faculty Panel

Adam Burgoyne, MD, PhD

UC San Diego

Kirema Garcia-Reyes, MD

Mount Sinai

Christopher Malone, MD

Washington University

The HCC webinar series is sponsored by:

CCF Webinar: Navigating Cholangiocarcinoma - A Patient's Journey with Interventional Oncology

SIO is proud to partner with the Cholangiocarcinoma Foundation for a compelling webinar featuring renowned interventional oncologists Christos Georgiades, MD, PhD, and Sarah White, MD, MS, FSIR, and cholangiocarcinoma patient, Lynn Lazzaro. Together, they explore how interventional oncology (IO) treatments, combined with a multidisciplinary team (MDT) approach, played a pivotal role in Lynn’s care. Discover the innovative techniques and compassionate care that have made a difference in Lynn's life and learn how interventional oncology can offer hope and effective solutions for complex cancer cases.

Faculty

Christos Georgiades, MD, PhD

Johns Hopkins Medicine

Lynn Statz Lazzaro, CPA, CFP, MST

Sarah White, MD, MS, FSIR, FCIRSE

Medical College of Wisconsin

Watch On-Demand

This webinar is in partnership with the Cholangiocarcinoma Foundation

Announcing the society of interventional oncology podcast

Meet The Data Podcast: Conversations with Leading Experts on the Role of HCC and Immunotherapy Podcast Series

The Society of Interventional Oncology (SIO) is proud to launch its brand-new podcast, featuring a four-part podcast series showcasing discussions on pivotal trials that established immunotherapy’s role in advanced HCC. Search for the “Society of Interventional Oncology Podcast” in your favorite podcast app. Supported by an educational grant from AstraZeneca.

HCC Focus

Landmark trials in hepatocellular carcinoma

Immunotherapy

Cutting-edge treatments

Expert Insights

Listen on-demand

Listen on Spotify Listen on Apple

Episode One — Local Therapy vs. Combination Therapy: What’s Changing in Liver Cancer Treatment?

Join experts Chris Malone, MD and Lingling Du, MD as they explore the evolving landscape of liver cancer treatment. Moderated by Edward Kim, MD and Cynthia De la Garza, MD this episode dives into the latest clinical evidence supporting combination therapies and discusses the real-world challenges of implementing them. Learn how patient selection, tumor biology, and treatment risks are shaping the future of care.

Listen on Spotify Listen on Apple

Episode Two — Comparing LEAP-012 vs. EMERALD-1 Study: Decoding the Data

What do two of the most talked-about liver cancer trials reveal about the future of immunotherapy? Riad Salem, MD, MBA and Stephen Chan, MBBS, MRCP, FHKCP, FHKAM, FRCP, FRCP, MD discuss the LEAP-012 and EMERALD-1 studies with moderators Venkatesh Krishmasamy, MD, and Sean Golden, MD. This episode compares trial designs, outcomes, and implications for clinical practice—offering insights into how these findings could reshape treatment protocols.

Listen on Spotify Listen on Apple

Episode Three — Role of (neo)adjuvant immunotherapy pre-transplant vs. Adjuvant immunotherapy post-transplant

Should immunotherapy come before or after transplant? Experts Parissa Tabrizian, MD and Beau Toskich, MD explore one of the most critical questions in transplant oncology: when is the right time to introduce immunotherapy? Moderated by Bill Rilling, MD, the discussion dives into the clinical evidence surrounding neoadjuvant and adjuvant immuno-oncology (IO) therapies in transplant settings.

Listen on Spotify Listen on Apple

Episode Four — Ablation vs. Ablation + Combination Immune Therapy

Is combining ablation with immune therapy lead to better outcomes? Gentry King, MD and Isabel Newton, MD explore this question with moderators Elena Violari, MD and Greg Pommier. Discover how the synergy between local and systemic treatments is being studied, and what it means for patient selection, recurrence rates, and long-term survival.

Listen on Spotify Listen on Apple